)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Sichuan Biokin Pharmaceutical Co
Sichuan Biokin Pharmaceutical Co (688506) investor relations material
Sichuan Biokin Pharmaceutical Co Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary30 Oct, 2026
Executive summary
Q3 revenue was RMB 1.907bn, up 0.63% YoY; net income was RMB 932.3m, up 49.54%, while 9M net loss widened to RMB 704.9m.
9M R&D investment reached RMB 2.367bn, exceeding revenue; operating cash outflow was RMB 2.168bn.
Financial highlights
9M revenue was RMB 2.094bn, up 1.35% YoY; total operating costs reached RMB 2.832bn, including RMB 2.045bn in R&D expenses.
9M operating loss was RMB 575.0m and net loss RMB 704.9m, versus net loss of RMB 494.5m in 9M 2025; income tax expense fell to RMB 121.1m from RMB 308.9m.
Q3 net income was RMB 932.3m and adjusted net income RMB 918.3m; the reported increase was attributed mainly to lower income tax expense.
9M non-recurring gains totaled RMB 65.6m, including RMB 65.2m in fair-value gains.
Key financial ratios and metrics
9M R&D investment rose 33.54% YoY to RMB 2.367bn; R&D was 113.03% of revenue, up 27.24 percentage points.
Q3 basic and diluted EPS were both RMB 2.26, up 45.81%; 9M basic and diluted EPS were both negative RMB 1.71 versus negative RMB 1.23.
Weighted average ROE was 18.44% for Q3, up 3.59 percentage points; the 9M figure was negative 11.66%, down 1.93 percentage points.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sichuan Biokin Pharmaceutical Co
- Net loss deepened on surging R&D, but global first-in-class drug approvals marked a milestone.688506
Q2 2026 - Revenue surged 1,685% year-over-year to RMB 5.55B, with net profit at RMB 4.67B on BMS deal.688506Q2 2024
- Net profit surged to RMB 3.71 billion on record revenue, fueled by a major BMS licensing deal.688506Q4 2024
- Nine-month revenue surged 1,399% to RMB 5.66B, with net profit at RMB 4.07B on BMS payment.688506Q3 2024
- Revenue plummeted and losses deepened as R&D investment surged to over 600% of sales.688506Q2 2025
- Revenue plunged and net loss widened as R&D spending surged and IP licensing income vanished.688506Q1 2025
- Revenue dropped 56.7% and net loss reached RMB 1.05 billion amid surging R&D investment.688506Q4 2025
- Milestone revenue from BMS offset a sharp year-over-year revenue decline and deepened losses.688506Q3 2025
Next Sichuan Biokin Pharmaceutical Co earnings date
Q4 202616 Apr, 2027
Sichuan Biokin Pharmaceutical Co
Next Sichuan Biokin Pharmaceutical Co earnings date
Q4 202616 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)